No Data
No Data
Changzhou Qianhong Biopharma CO.,LTD's (SZSE:002550) Market Cap up CN¥387m Last Week, Benefiting Both Retail Investors Who Own 49% as Well as Insiders
Changzhou Qianhong Biopharma (002550.SZ): The Qianmu project is scheduled to start production within the year.
Changzhou Qianhong Biopharma (002550.SZ) stated on the investor interaction platform on September 20 that the Qianmu project is currently under intense construction and is planned to be put into operation within this year. The construction of the Qianhong (Hubei) active pharmaceutical ingredient base project is also currently in progress.
Investors Appear Satisfied With Changzhou Qianhong Biopharma CO.,LTD's (SZSE:002550) Prospects
Changzhou Qianhong Biopharma: Summary of Half-Year Report in 2024.
Changzhou Qianhong Biopharma: Half-year report for the year 2024.
Changzhou Qianhong Biopharma (002550.SZ): Net income in the first half of the year reached 0.183 billion yuan, a year-on-year increase of 53.57%.
On August 15, Gelunhui reported that Changzhou Qianhong Biopharma (002550.SZ) published its 2024 interim report, achieving revenue of 0.856 billion yuan and net income attributable to shareholders of listed companies of 0.183 billion yuan in the first half of the year, an increase of 53.57% compared to the same period last year. The net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was 0.179 billion yuan, an increase of 60.64% compared to the same period last year, with basic earnings per share of 0.1457 yuan. The main reason is due to the company's active response to the severe and complex ecological environment of the domestic and foreign pharmaceutical industry, timely grasping industry global strategy opportunities, and implementing scientific and rational production, supply, and marketing.
No Data
No Data